Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Am J Obstet Gynecol. 2012 Sep;207(3 Suppl):S17-20. doi: 10.1016/j.ajog.2012.06.070. Epub 2012 Jul 9.
Influenza vaccination is a cornerstone of influenza prevention efforts among pregnant women. Prior to 2005, data from studies conducted on pregnant women were limited, with much of the supporting evidence coming from influenza vaccine studies conducted among nonpregnant, age-matched populations. Since 2005, however, an increasing number of studies have demonstrated the safety and immunogenicity of influenza vaccine for pregnant women, including evidence of maternal transfer of antibody. In addition, the clinical benefit of influenza vaccination, both for the mother and infant, was demonstrated in a landmark randomized clinical trial conducted in Bangladesh. Additional randomized clinical trials with laboratory-confirmed influenza as the primary outcome are underway in countries without a current influenza vaccination program, but such trials are unlikely to be conducted in the United States or other countries that already recommend the vaccination of pregnant women. However, current evidence supports the safety and immunogenicity of inactivated influenza vaccine and its effectiveness in reducing the risk of influenza-related illness among pregnant women.
流感疫苗接种是孕妇预防流感工作的基石。在 2005 年之前,针对孕妇进行的研究数据有限,大部分支持证据来自针对非孕妇、年龄匹配人群进行的流感疫苗研究。然而,自 2005 年以来,越来越多的研究表明流感疫苗在孕妇中的安全性和免疫原性,包括母体抗体转移的证据。此外,在孟加拉国进行的一项具有里程碑意义的随机临床试验证明了流感疫苗接种对母亲和婴儿的临床益处。在没有当前流感疫苗接种计划的国家,正在进行更多以实验室确诊的流感为主要结局的随机临床试验,但在美国或其他已经建议孕妇接种疫苗的国家,不太可能进行此类试验。然而,目前的证据支持灭活流感疫苗的安全性和免疫原性,以及其在降低孕妇患流感相关疾病风险方面的有效性。